32 found
Order:
Disambiguations:
Jeffrey P. Kahn [32]Jeffrey Paul Kahn [1]
  1.  5
    Susan M. Wolf, Frances P. Lawrenz, Charles A. Nelson, Jeffrey P. Kahn, Mildred K. Cho, Ellen Wright Clayton, Joel G. Fletcher, Michael K. Georgieff, Dale Hammerschmidt, Kathy Hudson, Judy Illes, Vivek Kapur, Moira A. Keane, Barbara A. Koenig, Bonnie S. LeRoy, Elizabeth G. McFarland, Jordan Paradise, Lisa S. Parker, Sharon F. Terry, Brian van Ness & Benjamin S. Wilfond (2008). Managing Incidental Findings in Human Subjects Research: Analysis and Recommendations. Journal of Law, Medicine & Ethics 36 (2):219-248.
    No consensus yet exists on how to handle incidental fnd-ings in human subjects research. Yet empirical studies document IFs in a wide range of research studies, where IFs are fndings beyond the aims of the study that are of potential health or reproductive importance to the individual research participant. This paper reports recommendations of a two-year project group funded by NIH to study how to manage IFs in genetic and genomic research, as well as imaging research. We conclude that researchers (...)
    Direct download (3 more)  
     
    Export citation  
     
    My bibliography   27 citations  
  2. Leili Fatehi, Susan M. Wolf, Jeffrey McCullough, Ralph Hall, Frances Lawrenz, Jeffrey P. Kahn, Cortney Jones, Stephen A. Campbell, Rebecca S. Dresser, Arthur G. Erdman, Christy L. Haynes, Robert A. Hoerr, Linda F. Hogle, Moira A. Keane, George Khushf, Nancy M. P. King, Efrosini Kokkoli, Gary Marchant, Andrew D. Maynard, Martin Philbert, Gurumurthy Ramachandran, Ronald A. Siegel & Samuel Wickline (2012). Recommendations for Nanomedicine Human Subjects Research Oversight: An Evolutionary Approach for an Emerging Field. Journal of Law, Medicine and Ethics 40 (4):716-750.
    No categories
    Direct download (2 more)  
     
    Export citation  
     
    My bibliography   4 citations  
  3. Susan M. Wolf, Frances P. Lawrenz, Charles A. Nelson, Jeffrey P. Kahn, Mildred K. Cho, Ellen Wright Clayton, Joel G. Fletcher, Michael K. Georgieff, Dale Hammerschmidt, Kathy Hudson, Judy Illes, Vivek Kapur, Moira A. Keane, Barbara A. Koenig, Bonnie S. LeRoy, Elizabeth G. McFarland, Jordan Paradise, Lisa S. Parker, Sharon F. Terry, Brian Van Ness & Benjamin S. Wilfond (2008). Managing Incidental Findings in Human Subjects Research: Analysis and Recommendations. Journal of Law, Medicine and Ethics 36 (2):219-248.
    No categories
    Direct download (2 more)  
     
    Export citation  
     
    My bibliography   7 citations  
  4.  1
    Baruch Brody, Nancy Dubler, Jeff Blustein, Arthur Caplan, Jeffrey P. Kahn, Nancy Kass, Bernard Lo, Jonathan Moreno, Jeremy Sugarman & Laurie Zoloth (2002). The Task Force Responds. Hastings Center Report 32 (3):22-23.
    Direct download (3 more)  
     
    Export citation  
     
    My bibliography   7 citations  
  5.  11
    Leili Fatehi, Susan M. Wolf, Jeffrey McCullough, Ralph Hall, Frances Lawrenz, Jeffrey P. Kahn, Cortney Jones, Stephen A. Campbell, Rebecca S. Dresser, Arthur G. Erdman, Christy L. Haynes, Robert A. Hoerr, Linda F. Hogle, Moira A. Keane, George Khushf, Nancy M. P. King, Efrosini Kokkoli, Gary Marchant, Andrew D. Maynard, Martin Philbert, Gurumurthy Ramachandran, Ronald A. Siegel & Samuel Wickline (2012). Recommendations for Nanomedicine Human Subjects Research Oversight: An Evolutionary Approach for an Emerging Field. Journal of Law, Medicine & Ethics 40 (4):716-750.
    The nanomedicine field is fast evolving toward complex, “active,” and interactive formulations. Like many emerging technologies, nanomedicine raises questions of how human subjects research (HSR) should be conducted and the adequacy of current oversight, as well as how to integrate concerns over occupational, bystander, and environmental exposures. The history of oversight for HSR investigating emerging technologies is a patchwork quilt without systematic justification of when ordinary oversight for HSR is enough versus when added oversight is warranted. Nanomedicine HSR provides an (...)
    Direct download (4 more)  
     
    Export citation  
     
    My bibliography   1 citation  
  6.  4
    Jeffrey P. Kahn (2006). What Happens When Politics Discovers Bioethics? Hastings Center Report 36 (3):10-10.
    Direct download (3 more)  
     
    Export citation  
     
    My bibliography   2 citations  
  7.  10
    Susan M. Wolf & Jeffrey P. Kahn (2005). Bioethics Matures:. Hastings Center Report 35 (4):22-24.
    Direct download (4 more)  
     
    Export citation  
     
    My bibliography   2 citations  
  8.  6
    John A. Robertson, Jeffrey P. Kahn & John E. Wagner (2002). CONCEPTION to Obtain Hematopoietic Stem Cells. Hastings Center Report 32 (3):34-40.
    Direct download (3 more)  
     
    Export citation  
     
    My bibliography   2 citations  
  9.  40
    Jeffrey P. Kahn & Anna C. Mastroianni (2004). Creating a Stem Cell Donor: A Case Study in Reproductive Genetics. Kennedy Institute of Ethics Journal 14 (1):81-96.
    : During the nearly 10 years since its introduction, preimplantation genetic diagnosis (PGD) has been used predominantly to avoid giving birth to a child with identified genetic disease. Recently, PGD was used by a couple not only to test IVF-created embryos for genetic disease, but also to test for a nondisease trait related to immune compatibility with a child in the family in need of an hematopoetic stem cell transplant. This article describes the case, raises some ethical and policy issues, (...)
    Direct download (6 more)  
     
    Export citation  
     
    My bibliography   1 citation  
  10.  39
    Jeffrey P. Kahn (2003). Three Views of Organ Procurement Policy: Moving Ahead or Giving Up? Kennedy Institute of Ethics Journal 13 (1):45-50.
    : The supply of organs for transplant remains inadequate to meet the needs of waiting patients, in spite of many programs and approaches to increase rates of donation. Over the years there have been numerous proposals to introduce schemes that would move toward the outright sale of organs. Three articles in this issue of the Journal propose methods for increasing organ supply—two by moving toward a market approach and the third by advocating a change in social culture. All three suffer (...)
    Direct download (6 more)  
     
    Export citation  
     
    My bibliography   1 citation  
  11.  10
    Susan M. Wolf, Jeffrey P. Kahn & John E. Wagner (2003). Using Preimplantation Genetic Diagnosis to Create a Stem Cell Donor: Issues, Guidelines & Limits. Journal of Law, Medicine & Ethics 31 (3):327-339.
  12.  15
    Susan M. Wolf & Jeffrey P. Kahn (2005). Bioethics Matures: The Field Faces the Future. Hastings Center Report 35 (4):22-24.
    Direct download (4 more)  
     
    Export citation  
     
    My bibliography  
  13.  4
    Jeffrey P. Kahn (1991). Genetic Harm: Bitten by the Body That Keeps You? Bioethics 5 (4):289–308.
    Direct download (6 more)  
     
    Export citation  
     
    My bibliography   4 citations  
  14.  26
    Robert E. McKeown, Douglas L. Weed, Jeffrey P. Kahn & Michael A. Stoto (2003). American College of Epidemiology Ethics Guidelines: Foundations and Dissemination. Science and Engineering Ethics 9 (2):207-214.
    Epidemiology is a core science of public health, focusing on research related to the distribution and determinants of both positive and adverse health states and events and on application of knowledge gained to improve public health. The American College of Epidemiology (ACE) is a professional organization devoted to the professional practice of epidemiology. As part of that commitment, and in response to concerns for more explicit attention to core values and duties of epidemiologists in light of emerging issues and increased (...)
    Direct download (7 more)  
     
    Export citation  
     
    My bibliography   1 citation  
  15. Stella Gonzalez Arnal, Donald Chalmers, David Kum-Wah Chan, Margaret Coffey, Jo Ann T. Croom, Mylène Deschênes, Henrich Ganthaler, Yuri Gariev, Ryuichi Ida, Jeffrey P. Kahn, Martin O. Makinde, Anna C. Mastroianni, Katharine R. Meacham, Bushra Mirza, Michael J. Morgan, Dianne Nicol, Edward Reichman, Susan E. Wallace & Larissa P. Zhiganova (2004). Cross-Cultural Biotechnology: A Reader. Rowman & Littlefield Publishers.
    This book is a rich blend of analyses by leading experts from various cultures and disciplines. A compact introduction to a complex field, it illustrates biotechnology's profound impact upon the environment and society. Moreover, it underscores the vital relevance of cultural values. This book empowers readers to more critically assess biotechnology's value and effectiveness within both specific cultural and global contexts.
     
    Export citation  
     
    My bibliography   1 citation  
  16. John A. Robertson, Jeffrey P. Kahn & John E. Wagner (forthcoming). Conception. Hastings Center Report.
     
    Export citation  
     
    My bibliography  
  17. Susan M. Wolf, Jeffrey P. Kahn & John E. Wagner (2003). Using Preimplantation Genetic Diagnosis to Create a Stem Cell Donor: Issues, Guidelines & Limits. Journal of Law, Medicine and Ethics 31 (3):327-339.
    No categories
    Direct download (2 more)  
     
    Export citation  
     
    My bibliography   1 citation  
  18.  7
    Tom L. Beauchamp, Howard Brody, Franklin G. Miller, Alexander S. Curtis, Martina Darragh, Patricia Milmoe, Ronald M. U. S. Green, Sharona Hoffman, Edmund G. Howe & Jeffrey P. Kahn (2003). By Author BAGHERI, Alireza. Criticism of “Brain. Kennedy Institute of Ethics Journal 13 (4):407-09.
    No categories
    Direct download  
     
    Export citation  
     
    My bibliography  
  19.  20
    Jeffrey P. Kahn (2007). Organs and Stem Cells: Policy Lessons and Cautionary Tales. Hastings Center Report 37 (2):11-12.
    Direct download (6 more)  
     
    Export citation  
     
    My bibliography  
  20.  5
    Susan M. Wolf & Jeffrey P. Kahn (2007). Genetic Testing and the Future of Disability Insurance: Ethics, Law & Policy. Journal of Law, Medicine & Ethics 35 (s2):6-32.
    Predictive genetic testing poses fundamental questions for disability insurance, a crucial resource funding basic needs when disability prevents income from work. This article, from an NIH-funded project, presents the first indepth analysis of the challenging issues: Should disability insurers be permitted to consider genetics and exclude predicted disability? May disabilities with a recognized genetic basis be excluded from coverage as pre-existing conditions? How can we assure that private insurers writing individual and group policies, employers, and public insurers deal competently and (...)
    Direct download (3 more)  
     
    Export citation  
     
    My bibliography  
  21.  2
    Jeffrey P. Kahn & Susan M. Wolf (2007). Understanding the Role of Genetics in Disability Insurance. Journal of Law, Medicine & Ethics 35 (s2):5-5.
    Direct download (3 more)  
     
    Export citation  
     
    My bibliography  
  22.  5
    Jeffrey P. Kahn (2007). Baseball, Alcohol and Public Health. American Journal of Bioethics 7 (7):3.
    Direct download (4 more)  
     
    Export citation  
     
    My bibliography  
  23.  5
    Jeffrey P. Kahn (1991). Commentary on Zohar's "Prospects For'genetic Therapy'- Can a Person Benefit From Being Altered?". Bioethics 5 (4):312–317.
    Direct download (6 more)  
     
    Export citation  
     
    My bibliography  
  24.  2
    Jeffrey P. Kahn (2007). Why Public Health and Politics Don't Mix. American Journal of Bioethics 7 (11):3 – 4.
    Direct download (4 more)  
     
    Export citation  
     
    My bibliography  
  25.  2
    Jeffrey P. Kahn & Anna C. Mastroianni (1996). Introduction. Kennedy Institute of Ethics Journal 6 (3):ix-xi.
    Direct download (2 more)  
     
    Export citation  
     
    My bibliography  
  26.  2
    Jeffrey P. Kahn (2009). Commentary: Who's Afraid of the RAC? Lessons From the Oversight of Controversial Science. Journal of Law, Medicine & Ethics 37 (4):685-687.
    This commentary asks what we can learn from our oversight of controversial science and how can we do better in the future? After briefly examining the history of gene transfer research oversight, some observations are offered for the oversight of nanobiotechnology and other emerging areas of science.
    Direct download (3 more)  
     
    Export citation  
     
    My bibliography  
  27.  1
    Anna C. Mastroianni & Jeffrey P. Kahn (1996). Introduction. Kennedy Institute of Ethics Journal 6 (3):ix-xi.
    Direct download (3 more)  
     
    Export citation  
     
    My bibliography  
  28. Jeffrey P. Kahn (2009). Commentary: Who's Afraid of the RAC? Lessons From the Oversight of Controversial Science. Journal of Law, Medicine and Ethics 37 (4):685-687.
    No categories
    Direct download (2 more)  
     
    Export citation  
     
    My bibliography  
  29. Jeffrey P. Kahn (2005). Letter to the Editor. American Journal of Bioethics 5 (3):W13-W13.
    Direct download (3 more)  
     
    Export citation  
     
    My bibliography  
  30. Jeffrey P. Kahn & Susan M. Wolf (2007). Understanding the Role of Genetics in Disability Insurance. Journal of Law, Medicine and Ethics 35 (s2):5-5.
    No categories
    Direct download (2 more)  
     
    Export citation  
     
    My bibliography  
  31. Susan M. Wolf, Jeffrey P. Kahn & John E. Wagner (2003). Clinical, Ethical, and Legal Issues in Using Preimplantation Genetic Diagnosis to Create a Stem Cell Donor. Journal of Law, Medicine & Ethics 31:327-39.
     
    Export citation  
     
    My bibliography  
  32. Susan M. Wolf & Jeffrey P. Kahn (2007). Genetic Testing and the Future of Disability Insurance: Ethics, Law & Policy. Journal of Law, Medicine and Ethics 35 (s2):6-32.
    No categories
    Direct download (2 more)  
     
    Export citation  
     
    My bibliography